SCHEMBL717467

SCHEMBL717467

Cc1nc(N)nc(N[C@@H](C)c2cc3cccc(C)c3nc2N2CCNC(=O)CC2)n1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 12/20 0.41
CCNT1 O60563 1/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CDK9 P50750 1/20 0.35
TSHR P16473 2/20 0.34
ALOX15 P16050 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PIK3CA P42336 1/20 0.34
MTOR P42345 1/20 0.34
KDM4E B2RXH2 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CLK1 P49759 1/20 0.33
MBOAT4 Q96T53 1/20 0.33
SOS1 Q07889 1/20 0.33
HRH4 Q9H3N8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716805 0.92 PIK3CD (0.40) PIK3CDTSHRALOX15CASP1CASP7
SCHEMBL715342 0.92 PIK3CD (0.37) PIK3CDCCNT1CCNA2CDK2CDK9
SCHEMBL714115 0.89 PIK3CD (0.44) PIK3CDPIK3CAMTOR
SCHEMBL715604 0.88 PIK3CD (0.47) PIK3CDTSHRALOX15CASP1CASP7
SCHEMBL716189 0.85 TSHR (0.47) PIK3CDTSHRALOX15CASP1CASP7
SCHEMBL713510 0.84 PIK3CD (0.38) PIK3CDSOS1HRH4
SCHEMBL713509 0.84 PIK3CD (0.38) PIK3CDSOS1HRH4
SCHEMBL715520 0.83 PIK3CD (0.46) PIK3CDTSHRALOX15CASP1CASP7
SCHEMBL15875803 0.83 TSHR (0.38) PIK3CDTSHRALOX15CASP1CASP7
SCHEMBL718088 0.81 PIK3CD (0.42) PIK3CDPIK3CAMTORSOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP claimed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US claimed
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 PIK3CD 12/4885CCNT1 3273/4885CCNA2 2631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.